drugset / Trial / NCT05036317
Empagliflozin for the Treatment of Postprandial Hypoglycemia
Phase 3
Terminated
40 enrolled
University Hospital, Basel, Switzerland
Boehringer Ingelheim · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This randomized trial is to test whether a treatment with empagliflozin is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.
Timeline
- Start
- 2022-03-11
- Primary completion
- 2024-08-05
- Completion
- 2024-08-05
Outcome
Outcome not reported
Stopped: “Early terminated after prespecified interim analysis due to lack of efficacy. No relevant safety signals.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | Oral |